US2020354428A9PendingUtilityA9
Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
Assignee: WISCONSIN ALUMNI RES FOUNDPriority: Jun 23, 2013Filed: Aug 22, 2018Published: Nov 12, 2020
Est. expiryJun 23, 2033(~6.9 yrs left)· nominal 20-yr term from priority
C07K 14/635A61K 38/00
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described are polypeptide analogs of parathyroid hormone (PTH) that include an unnatural amino acid substitution at positions 7 or 8 from the N-terminus of the polypeptide. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated, unnatural peptide analogue comprising:
PTH, a parathyroid hormone receptor (PTHR-1, PTHR-2) agonist-effective fragment of PTH, a parathyroid hormone related protein (PTHrP), a PTHR-1 or PTHR-2 agonist-effective fragment of PTHrP, M-PTH, a PTHR-1 or PTHR-2 agonist-effective fragment of M-PTH, BA058, or a PTHR-1 or PTHR-2 agonist-effective fragment of BA058, in which at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a β-amino acid residue or a (D)-α-amino acid; and salts thereof.
2 . The peptide analogue of claim 1 , wherein the at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a β 2 -amino acid residue.
3 . The peptide analogue of claim 2 , wherein the at least one naturally occurring (L)-α-amino acid residue at 6, 7, or 8 from the N-terminus is replaced with a β 2 -amino acid residue having a side-chain identical to the (L)-α-amino acid residue it replaces.
4 . The peptide analogue of claim 1 , wherein the at least one naturally occurring (L)-α-amino acid residue at 6, 7, or 8 from the N-terminus is replaced with a β 3 -amino acid residue.
5 . The peptide analogue of claim 4 , wherein the at least one naturally occurring (L)-α-amino acid residue at 6, 7, or 8 from the N-terminus is replaced with a β 3 -amino acid residue having a side-chain identical to the (L)-α-amino acid residue it replaces.
6 . The peptide analogue of claim 1 , wherein the at least one naturally occurring (L)-α-amino acid residue at 6, 7, or 8 from the N-terminus is replaced with a (D)-α-amino acid.
7 . The peptide analogue of claim 6 , wherein the at least one naturally occurring (L)-α-amino acid residue at 6, 7, or 8 from the N-terminus is replaced with a (D)-α-amino acid residue having a side-chain identical to the (L)-α-amino acid residue it replaces.
8 . The peptide analogue of claim 1 , selected from the group consisting of
(SEQ. ID. NO: 8)
SVSEIQ L MHNLGKHLNSMERVEWLRKKLQDVHNF
(SEQ. ID. NO: 10)
SVSEIQ MHNLGKHLNSMERVEWLRKKLQDVHNF
and
(SEQ. ID. NO: 12)
SVSEIQL n L HNLGKHLNSMERVEWLRKKLQDVHNF
(SEQ. ID. NO: 14)
S VSEIQ L MHNLGKHLNSMERVEWLRKKLQDVHNF
(SEQ. ID. NO: 15)
S V SEI Q LMHNLGKHLNSMERVEWLRKKLQDVHNF
wherein L=(R*) β 2 leucine;
L=(D)-leucine; and
n L=(R*)-β 2 -norleucine.
Q=β 3 glutamine
S=β 2 serine.
9 . The peptide analogue of claim 1 , in which at least one additional naturally occurring (L)-α-amino acid residue at position 1 or 2 from the N-terminus is replaced with a β-amino acid residue or a (D)-α-amino acid.
10 . An isolated, unnatural peptide analogue consisting of:
PTH, a parathyroid hormone receptor (PTHR-1, PTHR-2) agonist-effective fragment of PTH, a parathyroid hormone related protein (PTHrP), a PTHR-1 or PTHR-2 agonist-effective fragment of PTHrP, M-PTH, a PTHR-1 or PTHR-2 agonist-effective fragment of M-PTH, BA058, or a PTHR-1 or PTHR-2 agonist-effective fragment of BA058, in which at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a β-amino acid residue or a (D)-α-amino acid; and salts thereof.
11 . The peptide analogue of claim 10 , wherein the at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a β 2 -amino acid residue.
12 . The peptide analogue of claim 11 , wherein the at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a β 2 -amino acid residue having a side-chain identical to the (L)-α-amino acid residue it replaces.
13 . The peptide analogue of claim 10 , wherein the at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a β 3 -amino acid residue.
14 . The peptide analogue of claim 13 , wherein the at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a β 3 -amino acid residue having a side-chain identical to the (L)-α-amino acid residue it replaces.
15 . The peptide analogue of claim 10 , wherein the at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a (D)-α-amino acid.
16 . The peptide analogue of claim 15 , wherein the at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a (D)-α-amino acid residue having a side-chain identical to the (L)-α-amino acid residue it replaces.
17 . The peptide analogue of claim 10 , selected from the group consisting of
(SEQ. ID. NO: 8)
SVSEIQ L MHNLGKHLNSMERVEWLRKKLQDVHNF
(SEQ. ID. NO: 10)
SVSEIQ MHNLGKHLNSMERVEWLRKKLQDVHNF
and
(SEQ. ID. NO: 12)
SVSEIQL n L HNLGKHLNSMERVEWLRKKLQDVHNF
(SEQ. ID. NO: 14)
S VSEIQ L MHNLGKHLNSMERVEWLRKKLQDVHNF
(SEQ. ID. NO: 15)
S V SEI Q LMHNLGKHLNSMERVEWLRKKLQDVHNF
wherein L=(R*) β 2 leucine;
L=(D)-leucine; and
n L=(R*)-β 2 -norleucine.
Q=β 3 glutamine
S=β 2 serine.
18 . The peptide analogue of claim 10 , in which at least one additional naturally occurring (L)-α-amino acid residue at position 1 or 2 from the N-terminus is replaced with a β-amino acid residue or a (D)-α-amino acid.
19 . A pharmaceutical composition for treating hypoparathyroidism, the composition comprising a parathyroid hormone receptor agonist-effective amount of PTH, a parathyroid hormone receptor (PTHR-1, PTHR-2) agonist-effective fragment of PTH, a parathyroid hormone related protein (PTHrP), a PTHR-1 or PTHR-2 agonist-effective fragment of PTHrP, M-PTH, a PTHR-1 or PTHR-2 agonist-effective fragment of M-PTH, BA058, or a PTHR-1 or PTHR-2 agonist-effective fragment of BA058, in which at least one naturally occurring (L)-α-amino acid residue at position 6, 7, or 8 from the N-terminus is replaced with a β-amino acid residue or a (D)-α-amino acid; and pharmaceutically suitable salts thereof,
in combination with a pharmaceutically suitable carrier.
20 . A method of treating hypoparathyroidism in a mammalian subject, including a human subject, the method comprising administering to the subject a parathyroid hormone receptor agonist-effective amount of a pharmaceutical composition as recited in claim 19 .Join the waitlist — get patent alerts
Track US2020354428A9 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.